Lunasin is a 43-amino acid polypeptide with poly (L-aspartic acid) sequence at the carboxyl terminus. It is found naturally in soy, barley, and rye. This bioactive peptide is the subject of research in more than 80 peer-reviewed and published studies by more than 30 research institutions around the world. Lunasin research has been supported by 27 public and private funding sources and has resulted in 10 patents. Bodies of research include: cancer prevention, cholesterol/cardiovascular, inflammation, skin health and anti-aging.
Loma Linda university is currently conducting a human clinical trial which is designed to validate research from prior studies. The trial is analyzing the data collected on the cholesterol lowering effects of Lunasin, as well as inflammation, oxidative stress, immune enhancements, and its effects on metabolic syndrome.
Current research at Harvard university is an extension of the human clinical trials performed at Duke University on how Lunasin affects progression of ALS. The Harvard study expands on Duke’s research by looking at epigenetic biomarkers (histone acetylation levels). Gathering and analyzing this bloodwork data will show why Lunasin is effective and see where the benefits are occurring at the genetic level. Genome wide screening of gene expression will also look at the association between Lunasin’s mechanism of action, epigenetic biomarkers, as well as the symptomatic affects in ALS patients.
Dr. Richard Bedlack, Professor and Director of the ALS Clinic at Duke University, is conducting a study on Lunasin in 50 ALS patients. The Study is a first of a kind clinical study that is investigating the efficacy Lunasin in the support of ALS. It’s the fastest enrollment study ever produced in their history. The clinical trial is based on Mike McDuff, an ALS patient who showed a remarkable reversal after taking bioactive Lunasin. He gained back his weight, went off his feeding tube and could talk again. Not all people will have the same results, but it greatly improved Mike’s quality of life.
List of Studies
Below is a full list of studies concerning Lunasin beginning with the most recent. To see an abstract of the article click the article’s title. Links to full articles with free access have been provided when available.
The protective role of the Bowman-Birk protease inhibitor in soybean lunasin digestion: the effect of released peptides on colon cancer growth.
An effective and simple procedure to isolate abundant quantities of biologically active chemopreventive Lunasin Protease Inhibitor Concentrate (LPIC) from soybean.
Lunasin inhibits cell proliferation via apoptosis and reduces the production of proinflammatory cytokines in cultured rheumatoid arthritis synovial fibroblasts.
Lunasin sensitivity in non-small cell lung cancer cells is linked to suppression of integrin signaling and changes in histone acetylation.
Off-line two dimensional isoelectrofocusing-liquid chromatography/mass spectrometry (time of flight) for the determination of the bioactive peptide lunasin.
Efficient production of native lunasin with correct N-terminal processing by using the pH-induced self-cleavable Ssp DnaB mini-intein system in Escherichia coli.
Understanding Lunasin’s biology and potential as a cancer therapeutic by utilizing Drosophila genetics.
Antioxidant activity and protective effects of peptide lunasin against oxidative stress in intestinal Caco-2 cells.
Endocytic mechanism of internalization of dietary peptide lunasin into macrophages in inflammatory condition associated with cardiovascular disease.
Potential of Lunasin Orally-Administered in Comparison to Intraperitoneal Injection to Inhibit Colon Cancer Metastasis in Vivo.
Structural property of soybean lunasin and development of a method to quantify lunasin in plasma using an optimized immunoassay protocol.
The soybean peptide lunasin promotes apoptosis of mammary epithelial cells via induction of tumor suppressor PTEN: similarities and distinct actions from soy isoflavone genistein.
RGD-peptide lunasin inhibits Akt-mediated NF-κB activation in human macrophages through interaction with the αVβ3 integrin.
Bowman-Birk and Kunitz protease inhibitors among antinutrients and bioactives modified by germination and hydrolysis in Brazilian soybean cultivar BRS 133.
Analysis of lunasin in commercial and pilot plant produced soybean products and an improved method of lunasin purification.
Synthesis of the cancer preventive peptide lunasin by lactic acid bacteria during sourdough fermentation.
Lunasin potentiates the effect of oxaliplatin preventing outgrowth of colon cancer metastasis, binds to α5β1 integrin and suppresses FAK/ERK/NF-κB signaling.
Differential gene expression of RAW 264.7 macrophages in response to the RGD peptide lunasin with and without lipopolysaccharide stimulation.
Lunasin and Bowman-Birk protease inhibitor concentrations of protein extracts from enzyme-assisted aqueous extraction of soybeans.
Relationship between lunasin’s sequence and its inhibitory activity of histones H3 and H4 acetylation.
Differential expression of thrombospondin (THBS1) in tumorigenic and nontumorigenic prostate epithelial cells in response to a chromatin-binding soy peptide.
Lunasin induces apoptosis and modifies the expression of genes associated with extracellular matrix and cell adhesion in human metastatic colon cancer cells.
Soybean peptide lunasin suppresses in vitro and in vivo 7,12-dimethylbenz[a]anthracene-induced tumorigenesis.
Lunasin promotes apoptosis in human colon cancer cells by mitochondrial pathway activation and induction of nuclear clusterin expression.
The role of nutraceutical proteins and peptides in apoptosis, angiogenesis, and metastasis of cancer cells.
Amaranth lunasin-like peptide internalizes into the cell nucleus and inhibits chemical carcinogen-induced transformation of NIH-3T3 cells.
Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis.
Lunasin peptide purified from Solanum nigrum L. protects DNA from oxidative damage by suppressing the generation of hydroxyl radical via blocking fenton reaction.
Lunasin, with an arginine-glycine-aspartic acid motif, causes apoptosis to L1210 leukemia cells by activation of caspase-3.
Complementary roles in cancer prevention: protease inhibitor makes the cancer preventive peptide lunasin bioavailable.
Antioxidant and anti-inflammatory properties of cancer preventive peptide lunasin in RAW 264.7 macrophages.
Lunasin and lunasin-like peptides inhibit inflammation through suppression of NF-kappaB pathway in the macrophage.
Isolation, purification and characterisation of lunasin from defatted soybean flour and in vitro evaluation of its anti-inflammatory activity.
Bowman-Birk inhibitor and genistein among soy compounds that synergistically inhibit nitric oxide and prostaglandin E2 pathways in lipopolysaccharide-induced macrophages.
Analysis of soybean protein-derived peptides and the effect of cultivar, environmental conditions, and processing on lunasin concentration in soybean and soy products.
beta-Conglycinins among sources of bioactives in hydrolysates of different soybean varieties that inhibit leukemia cells in vitro.
Cancer-preventive peptide lunasin from Solanum nigrum L. inhibits acetylation of core histones H3 and H4 and phosphorylation of retinoblastoma protein (Rb).
Lunasin concentration in different soybean genotypes, commercial soy protein, and isoflavone products.
Dynamics of keratinocytes in vivo using HO labeling: a sensitive marker of epidermal proliferation state.
Barley lunasin suppresses ras-induced colony formation and inhibits core histone acetylation in mammalian cells.
Chemopreventive property of a soybean peptide (lunasin) that binds to deacetylated histones and inhibits acetylation.
Amino acid sequence of a soybean (Glycine max) seed polypeptide having a poly(L-aspartic acid) structure.